Phibro Animal Health (NASDAQ:PAHC) updated its FY19 earnings guidance on Monday. The company provided EPS guidance of $1.72-1.77 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.85. The company issued revenue guidance of $850-875 million, compared to the consensus revenue estimate of $851.06 million.
A number of research firms have weighed in on PAHC. BidaskClub cut Phibro Animal Health from a buy rating to a hold rating in a research report on Thursday, August 16th. Barclays increased their price objective on Phibro Animal Health from $31.00 to $33.00 and gave the stock an underweight rating in a research report on Thursday, July 5th. Credit Suisse Group increased their price objective on Phibro Animal Health from $39.00 to $42.00 and gave the stock a neutral rating in a research report on Wednesday, May 9th. Finally, Zacks Investment Research cut Phibro Animal Health from a buy rating to a hold rating in a research report on Thursday, May 10th. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Phibro Animal Health currently has a consensus rating of Hold and a consensus target price of $38.80.
Phibro Animal Health stock traded up $2.75 during mid-day trading on Monday, reaching $53.50. 425,500 shares of the company were exchanged, compared to its average volume of 103,750. Phibro Animal Health has a twelve month low of $32.05 and a twelve month high of $54.62. The company has a current ratio of 3.17, a quick ratio of 1.73 and a debt-to-equity ratio of 1.61. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of 35.43, a PEG ratio of 2.80 and a beta of 0.93.
In other news, insider Dean J. Warras sold 10,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $46.38, for a total transaction of $463,800.00. Following the completion of the transaction, the insider now directly owns 1,780 shares of the company’s stock, valued at approximately $82,556.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Bfi Co., Llc sold 30,000 shares of the stock in a transaction that occurred on Thursday, June 7th. The stock was sold at an average price of $46.06, for a total value of $1,381,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 460,940 shares of company stock valued at $22,026,956 over the last ninety days. 51.88% of the stock is owned by insiders.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.